Date: Sunday, October 21, 2018
Session Type: ACR Poster Session A
Session Time: 9:00AM-11:00AM
Background/Purpose: While the role of Rituximab (RTX) in controlling the clinical manifestations of Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) has been documented, the mechanisms underlying the interplay between B-cell depletion and pro-inflammatory status leading to clinical response remain unknown. This translational multicenter study explored changes in serologic variables following B-lymphocyte depletion by in vivo Rituximab (RTX) treatment in Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA) patients and investigated RTX in vitro effects on the activity of other immune cells and on the vascular endothelium.
Methods: Sixteen SLE patients and 16 RA patients treated with RTX were enrolled. Changes in circulating inflammatory mediators, oxidative stress markers, and NETosis-derived products were evaluated at baseline and after 3 months. Serum
Results: In vivo treatment of SLE and RA patients with RTX caused a significant decrease of disease activity along with a prominent alteration in circulating biomolecules related to inflammation, oxidative stress and NETosis. Reversion in altered expression of miRNAs regulating those molecules was also noticed. The in vitro treatment of SLE and RA purified lymphocytes with RTX significantly decreased the percentage of B
Conclusion: 1. The role of B cells in autoimmunity is not confined to the production of auto-antibodies, also playing important roles in shaping the outcome of pathological immune responses. 2. RTX induced an early re-assessment of the pro-inflammatory status in RA and SLE patients, involving a re-establishment of the homeostatic equilibrium in the immune system and the vascular wall, thus paving the way to more tailored therapeutic approaches.
Funded by PI-0285-2017, ISCIII, PI15/01333 and RIER RD16/0012/0015 co-funded with FEDER
To cite this abstract in AMA style:Lopez-Pedrera C, Cecchi I, Barbarroja N, Patiño-Trives AM, Luque Tevar M, Pérez Sánchez L, Ibáñez-Costa A, Arias de la Rosa I, Jiménez-Gómez Y, Radin M, Ortega-Castro R, Castro-Villegas MC, Calvo-Gutierrez J, Escudero-Contreras A, Cuadrado MJ, Sciascia S, Collantes Estevez E, Aguirre Zamorano MÁ, Perez-Sanchez C. Rituximab Induces an Early Re-Assessment of the Immune and Vascular Systems in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/rituximab-induces-an-early-re-assessment-of-the-immune-and-vascular-systems-in-patients-with-systemic-lupus-erythematosus-and-rheumatoid-arthritis/. Accessed October 28, 2020.
« Back to 2018 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/rituximab-induces-an-early-re-assessment-of-the-immune-and-vascular-systems-in-patients-with-systemic-lupus-erythematosus-and-rheumatoid-arthritis/